XML 24 R11.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUES
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
REVENUES REVENUES
Disaggregation of Revenues
The following table summarizes our Total revenues:
Three Months Ended September 30, 2024Three Months Ended September 30, 2023
(in millions)U.S.EuropeRest of WorldTotalU.S.EuropeRest of WorldTotal
Product sales:
HIV
Biktarvy$2,826 $375 $272 $3,472 $2,504 $313 $268 $3,085 
Descovy534 24 28 586 460 25 26 511 
Genvoya384 44 21 449 433 47 23 503 
Odefsey248 69 9 326 257 74 11 343 
Symtuza - Revenue share(1)
103 33 3 139 96 32 3 131 
Other HIV(2)
65 26 9 100 56 28 9 94 
Total HIV4,161 570 342 5,073 3,807 519 341 4,667 
Liver Disease
Sofosbuvir/Velpatasvir(3)
222 67 96 385 215 76 85 377 
Vemlidy126 11 95 232 112 9 106 228 
Other Liver Disease(4)
45 54 17 116 49 33 20 102 
Total Liver Disease393 132 207 733 376 119 211 706 
Veklury393 81 219 692 258 65 313 636 
Oncology
Cell Therapy
Tecartus63 29 6 98 64 27 4 96 
Yescarta145 182 60 387 197 154 40 391 
Total Cell Therapy208 211 66 485 261 181 45 486 
Trodelvy226 80 26 332 201 62 21 283 
Total Oncology433 291 92 816 462 243 65 769 
Other
AmBisome6 71 52 130 12 63 39 115 
Other(5)
47 8 16 71 69 9 23 101 
Total Other53 80 68 201 82 72 62 216 
Total product sales5,433 1,154 928 7,515 4,985 1,017 992 6,994 
Royalty, contract and other revenues17 13 1 30 32 23 1 56 
Total revenues$5,450 $1,167 $929 $7,545 $5,017 $1,040 $993 $7,051 
Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023
(in millions)U.S.EuropeRest of WorldTotalU.S.EuropeRest of WorldTotal
Product sales:
HIV
Biktarvy$7,726 $1,110 $814 $9,649 $7,104 $920 $717 $8,741 
Descovy1,339 75 82 1,496 1,314 75 86 1,475 
Genvoya1,088 138 66 1,292 1,305 157 81 1,544 
Odefsey705 217 30 952 754 223 33 1,011 
Symtuza - Revenue share(1)
338 101 9 448 278 101 10 390 
Other HIV(2)
190 96 36 322 192 91 38 321 
Total HIV11,386 1,737 1,038 14,160 10,949 1,568 965 13,482 
Liver Disease
Sofosbuvir/Velpatasvir(3)
737 230 299 1,266 643 250 266 1,159 
Vemlidy338 33 328 699 295 28 322 645 
Other Liver Disease(4)
134 148 55 337 113 112 64 289 
Total Liver Disease1,210 411 682 2,302 1,051 390 652 2,093 
Veklury784 204 473 1,461 607 227 630 1,465 
Oncology
Cell Therapy
Tecartus181 102 22 305 179 83 11 272 
Yescarta502 509 170 1,181 624 408 99 1,130 
Total Cell Therapy683 611 192 1,485 802 491 109 1,402 
Trodelvy655 217 88 960 551 169 44 764 
Total Oncology1,338 828 280 2,446 1,354 660 153 2,167 
Other
AmBisome37 210 176 424 39 192 150 381 
Other(5)
203 26 52 281 197 31 49 277 
Total Other241 236 228 705 236 224 199 658 
Total product sales14,958 3,416 2,700 21,074 14,196 3,069 2,599 19,864 
Royalty, contract and other revenues66 43 2 111 57 77 4 138 
Total revenues$15,024 $3,459 $2,703 $21,185 $14,253 $3,146 $2,603 $20,002 
_______________________________
(1)    Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”).
(2)    Includes Atripla, Complera/Eviplera, Emtriva, Sunlenca, Stribild, Truvada and Tybost.
(3)    Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”).
(4)    Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi, Sovaldi, Viread and Vosevi.
(5)    Includes Cayston, Jyseleca, Letairis, Ranexa and Zydelig.
Revenues Recognized from Performance Obligations Satisfied in Prior Years
The following table summarizes revenues recognized from performance obligations satisfied in prior years:
Three Months EndedNine Months Ended
September 30,September 30,
(in millions)2024202320242023
Revenue share with Janssen and royalties for licenses of intellectual property$173 $166 $545 $517 
Changes in estimates$146 $111 $388 $347 
Contract Balances
The following table summarizes our contract balances:
(in millions)September 30, 2024December 31, 2023
Contract assets$184 $117 
Contract liabilities$68 $109